Skymedic Risk Report

📜 Innovation & R&D

Despite its modest size, SkyMedic shows potential in innovation. The company's dedication to aesthetics, dermatology, gynecology, and medical devices highlights its commitment to fostering advancements within niche markets in pharmaceutical manufacturing. It strives to enhance its offerings continuously, driving growth and opportunities in the sector.

• SkyMedic was founded in 2010, a testament to over a decade of commitment to innovation.
• Specialties in areas like aesthetics and dermatology signal a focused approach to market innovation.
• The company's presence in Spain’s pharmaceutical manufacturing industry is marked by its specialty in medical devices, showcasing its innovative edge.

🛡️ Financial & Liquidity

Currently, no critical financial or liquidity risks are evident for SkyMedic. The company maintains a stable position within its niche, with no immediate reports of financial distress like bankruptcy, financial fraud, or supplier payment delays.

• The company has been established since 2010, indicating a sustained presence in the industry.
• Employee range suggests moderate operational scale, reducing potential financial pressure from large workforce liabilities.

⚖️ Legal & Regulatory

There are no significant legal or regulatory challenges facing SkyMedic at this time. The absence of sanctions, regulatory penalties, or legal compliance issues underscores a stable compliance posture.

• Regulatory adherence appears strong as there are no reports of penalties.
• Legal risks are well-managed with no lawsuits reported.

👥 Labor & Workforce

SkyMedic's workforce appears stable, with no signs of labor unrest or financial distress affecting employee payments. This stability is crucial for maintaining operational continuity and ensures employee morale and productivity remain intact.

• The company operates with an employee range of 11 to 50, indicating manageable workforce dynamics.
• No unpaid wages reported, which correlates with financial stability.

🏗️ Operational & Business Continuity

SkyMedic does not present any immediate operational risks that threaten business continuity. The company's consistent focus on specialized medical devices and pharmaceuticals supports its ongoing operational stability.

• Operations have supported specialized fields since 2010.
• No evident operational disruptions reported as of the latest news.

🏅 Awards & Recognition

Currently, there isn’t any significant recent recognition or award that highlights SkyMedic’s achievements within the industry. This might suggest an area ripe for potential growth or marketing focus.

• Recognition within the industry could boost company visibility and credibility.

SkyMedic seems to maintain a stable position with committed innovation and manageable workforce involving a focussed operational strategy. There are currently no evident severe risks, making it a potentially attractive medium-sized player for stakeholders in the pharmaceutical manufacturing niche.